Overview

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Status:
Active, not recruiting
Trial end date:
2024-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
Phase:
Phase 2
Details
Lead Sponsor:
ADC Therapeutics S.A.